The Bipolar Disorder (Manic Depression) drugs in development market research report provides comprehensive information on the therapeutics under development for Bipolar Disorder (Manic Depression), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Bipolar Disorder (Manic Depression). Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Bipolar Disorder (Manic Depression) and features dormant and discontinued products.

GlobalData tracks 59 drugs in development for Bipolar Disorder (Manic Depression) by 53 companies/universities/institutes. The top development phase for Bipolar Disorder (Manic Depression) is preclinical with 15 drugs in that stage. The Bipolar Disorder (Manic Depression) pipeline has 55 drugs in development by companies and four by universities/ institutes. Some of the companies in the Bipolar Disorder (Manic Depression) pipeline products market are: Johnson & Johnson, Suven Life Sciences and OWP Pharmaceuticals.

The key targets in the Bipolar Disorder (Manic Depression) pipeline products market include D2 Dopamine Receptor (Dopamine D2 Receptor or DRD2), 5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A), and 5-Hydroxytryptamine Receptor 1A (5 HT1A or G 21 or Serotonin Receptor 1A or HTR1A).

The key mechanisms of action in the Bipolar Disorder (Manic Depression) pipeline product include D2 Dopamine Receptor (Dopamine D2 Receptor or DRD2) Antagonist with 14 drugs in Pre-Registration. The Bipolar Disorder (Manic Depression) pipeline products include nine routes of administration with the top ROA being Oral and three key molecule types in the Bipolar Disorder (Manic Depression) pipeline products market including Small Molecule, and Synthetic Peptide.

Bipolar Disorder (Manic Depression) overview

Bipolar disorder, previously known as manic depression, is a mental health condition characterized by extreme mood swings that include emotional highs (mania or hypomania) and lows (depression). These mood shifts can significantly impact a person’s ability to function in daily life. The exact cause of bipolar disorder is not fully understood, but it is believed to involve a combination of genetic, biological, and environmental factors. Stressful life events or disruptions in neurotransmitter function in the brain may also contribute to the onset of symptoms.

For a complete picture of Bipolar Disorder (Manic Depression)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.